So far, potential targets already elaborated in clinical studies comprise the myeloid-lineage specific markers CD123 (IL-13 receptor alpha chain) [7], CD33 [8], and C-type lectin-like molecule 1 (CLL-1) [9], which is also expressed on AML cells that lack CD33. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.